YK-11: What the Research Actually Shows About This Myostatin Inhibitor

What Exactly Is YK-11?

YK-11 is a synthetic compound first described by Japanese chemist Yuichiro Kanno in a 2011 paper published in Biological and Pharmaceutical Bulletin [1]. Structurally, it is derived from 19-nor-testosterone, placing it closer to a steroidal scaffold than most SARMs, which are typically non-steroidal. Two proposed mechanisms have been reported in cell studies: partial agonism at the androgen receptor and suppression of myostatin, a protein that limits skeletal muscle growth.

The myostatin angle is what separates YK-11 marketing claims from those of other SARMs. Myostatin (also called GDF-8) normally acts as a brake on muscle fiber hypertrophy. Animals with genetic myostatin deletions develop dramatically larger muscles, a finding confirmed in both cattle breeds and rare human cases [2]. YK-11 proponents argue the compound mimics this effect pharmacologically.

The problem is that all myostatin-inhibition data for YK-11 comes from a single cell-line experiment. Kanno's 2011 paper showed that C2C12 mouse myoblasts treated with YK-11 produced more follistatin, an endogenous myostatin antagonist, compared with DHT-treated cells [1]. This is a mechanistically interesting result. It is not evidence that swallowing or injecting YK-11 inhibits myostatin in a living human being, raises muscle mass, or does so safely.

How Does YK-11 Compare to Other Popular SARMs?

Ostarine (MK-2866), LGD-4033, RAD-140, and cardarine (GW 501516) are frequently discussed alongside YK-11, but their evidence bases differ substantially. Ostarine has progressed furthest in human trials. A 12-week Phase II study (N=120) in cancer-related muscle wasting showed statistically significant lean mass gains of 1.4 kg versus placebo (P<0.001) [3]. LGD-4033 (ligandrol) has one published Phase I pharmacokinetic study showing dose-dependent lean mass increases at doses as low as 1 mg per day over 21 days [4].

RAD-140 (tesofensine is unrelated; RAD-140 is also called testolone) has primate data showing CNS neuroprotection and anabolic effects, but no completed Phase II trial in humans [5]. Cardarine (GW 501516) is not a SARM at all. It is a PPAR-delta agonist that was abandoned by GlaxoSmithKline in 2007 after it produced dose-dependent, multi-organ cancers in rat studies at durations exceeding 2 years [6]. The FDA has issued explicit warnings about cardarine [7].

Comparative Evidence Tier Table

| Compound | Mechanism | Completed Human Trials | Highest Evidence Level | |---|---|---|---| | Ostarine (MK-2866) | AR agonist | Phase II (N=120) | RCT data | | LGD-4033 | AR agonist | Phase I (N=76) | PK/PD data | | RAD-140 | AR agonist | None completed | Primate data | | YK-11 | AR + myostatin (proposed) | None | Cell line only | | Cardarine (GW 501516) | PPAR-delta agonist | None (abandoned) | Animal carcinogen |

YK-11 sits at the bottom of this table in terms of human evidence, sharing the lowest tier only with cardarine, which carries an active carcinogenicity signal.

What Does the Safety Data Actually Show?

There are no Phase I pharmacokinetic studies for YK-11 in humans. Half-life estimates of 6 to 10 hours circulating online are extrapolated from structural analogy to other 19-nor compounds, not from measured plasma concentration curves.

Case reports provide the only clinical safety signals available. A 2022 case published in ACG Case Reports Journal described a 26-year-old male who developed cholestatic hepatitis after a 4-week cycle of a product labeled as containing YK-11 [8]. Liver enzymes peaked at ALT 487 U/L (approximately 12 times the upper limit of normal). Symptoms resolved after cessation and supportive care, but the case illustrates how little clinical margin exists between reported doses and hepatotoxic thresholds.

Testosterone suppression is another documented concern. The androgen receptor agonism that drives YK-11's proposed anabolic effects also suppresses the hypothalamic-pituitary-gonadal (HPG) axis. Leutinizing hormone (LH) and follicle-stimulating hormone (FSH) suppression has been documented with structurally similar compounds including LGD-4033, where a 3-week Phase I study showed LH suppression from a baseline mean of 1.7 IU/L to 0.8 IU/L at the 1 mg dose [4]. Because YK-11 is a more potent partial androgen receptor agonist per its in vitro binding data, HPG suppression may be more pronounced, though this has not been measured prospectively.

Additional self-reported adverse effects from user surveys and forums (not peer-reviewed data) include joint pain, hair shedding, mood changes, and elevated hematocrit. These signals align with known class effects of androgenic compounds but cannot be attributed to YK-11 specifically given no controlled observations.

Legal and Regulatory Status

The FDA has not approved YK-11 for any indication. Under the Dietary Supplement Health and Education Act (DSHEA), products containing SARMs, including YK-11, cannot legally be sold as dietary supplements in the United States [9]. The FDA's 2017 guidance statement noted: "SARMs are unapproved drugs... not dietary supplements" and cited risks of "life-threatening reactions including liver toxicity" [9].

WADA listed SARMs under the S1 Anabolic Agents category of the Prohibited List, effective 2008, with explicit coverage of any non-steroidal and steroidal compound with androgen receptor activity [10]. YK-11 is detectable in urine by liquid chromatography-tandem mass spectrometry (LC-MS/MS) for up to 28 days post-administration based on anti-doping laboratory method validation studies. Any competitive athlete testing positive faces a standard 4-year ban for a first violation under the World Anti-Doping Code.

Purchasing and possessing YK-11 is not currently a federal criminal offense in the United States for personal use, but state laws vary, and importation from overseas suppliers creates customs and federal regulatory exposure.

Why Myostatin Inhibition Is Harder Than It Sounds

The myostatin biology argument for YK-11 is scientifically coherent in isolation. Myostatin is a validated target. Pharmaceutical-grade myostatin inhibitors have been developed and tested. Domagrozumab (PF-06252616), a myostatin-binding antibody studied by Pfizer, produced statistically significant improvements in muscle volume in Duchenne muscular dystrophy patients in a Phase II trial but did not meet its primary functional endpoint [11]. ACE-031, another myostatin pathway inhibitor tested by Acceleron Pharma, was halted after Phase II trials due to unexpected vascular adverse events including epistaxis and telangiectasias [12].

These drug failures involved purpose-built, pharma-grade biologics tested in controlled trials with safety monitoring. If dedicated myostatin inhibitors with clean target selectivity face significant safety hurdles, a small steroidal molecule interacting with both androgen receptors and the myostatin pathway simultaneously introduces a compounded, unstudied interaction risk.

The follistatin-upregulation signal Kanno reported in 2011 [1] has not been independently replicated in additional cell lines, animal models, or humans as of this writing. Single-paper, single-lab cell findings frequently fail to translate.

Testosterone Suppression and Post-Cycle Recovery

Any compound with meaningful androgen receptor agonist activity suppresses endogenous testosterone production. This is not a theoretical concern. The Bhasin et al. foundational testosterone dose-response study published in the New England Journal of Medicine confirmed that exogenous androgenic agents suppress LH and FSH in a concentration-dependent manner, reducing intratesticular testosterone and impairing spermatogenesis [13].

Recovery timelines after SARM use depend on the degree of HPG suppression and the individual's baseline axis function. In the LGD-4033 Phase I study, hormone levels had not fully returned to baseline in all participants by the 5-week follow-up visit after a 21-day exposure [4]. YK-11 users who experience significant HPG suppression may require weeks to months for recovery. A subset may not recover fully without clinical intervention.

Clinicians at HealthRX evaluate HPG axis recovery with serial LH, FSH, and total testosterone measurements taken at 4, 8, and 12 weeks post-cessation. If testosterone remains below 300 ng/dL at the 12-week mark, formal TRT evaluation or a monitored clomiphene citrate protocol becomes appropriate. Clomiphene citrate has documented utility in secondary hypogonadism recovery, with a 2019 review in Translational Andrology and Urology showing 73% of men achieved testosterone above 400 ng/dL within 3 months of treatment [14].

What Legitimate Alternatives Exist for Body Composition Goals?

For individuals seeking meaningful, evidence-backed body composition improvement, several options have substantially more human safety data than YK-11.

Resistance training with progressive overload remains the single best-studied anabolic intervention in healthy adults. A 2017 meta-analysis in the British Journal of Sports Medicine (N=1,079 across 49 studies) confirmed that resistance exercise produced mean lean mass gains of 1.1 kg over training periods averaging 20 weeks [15].

Semaglutide 2.4 mg (Wegovy) produced 14.9% mean total body weight loss at 68 weeks versus 2.4% for placebo in STEP-1 (N=1,961) [16], with favorable preservation of lean mass when combined with resistance training compared to diet alone.

Testosterone replacement therapy (TRT), when indicated by documented hypogonadism (total testosterone <300 ng/dL on two morning fasted measurements per Endocrine Society guidelines), produces well-characterized anabolic and body composition benefits with a 30-year safety literature [17]. Unlike YK-11, TRT is FDA-approved, dosed precisely, and monitored through established laboratory protocols.

Creatine monohydrate at 3-5 g per day has a 30-year safety record, is legal in sport, and a Cochrane-style systematic review published in the Journal of Strength and Conditioning Research (N=22 studies) showed a mean 8% increase in strength outcomes compared to placebo [18].

Who Is Buying YK-11 and What Are the Real Risks?

The typical YK-11 buyer is a male between 18 and 35 seeking anabolic effects without full testosterone shutdown, often guided by influencer or forum content that selectively emphasizes myostatin inhibition benefits while minimizing the absence of human safety data. A 2020 survey published in Performance Enhancement and Health found that 56% of SARM users reported obtaining their compounds from online retailers without any physician involvement, and 44% reported at least one adverse symptom they attributed to SARM use [19].

Product purity is an additional, underappreciated risk. A 2017 USADA analysis of 44 SARM products purchased online found that 52% contained doses different from the label, 39% contained additional unlabeled compounds, and 25% contained no detectable SARM at all [20]. A buyer of "YK-11" may receive a contaminated product, an overdosed product, or a structurally related but chemically distinct compound with entirely different receptor pharmacology.

The FDA's Center for Drug Evaluation and Research explicitly stated in its 2019 consumer advisory: "Selective androgen receptor modulators have not been shown to be safe and effective for any indication, and may cause adverse effects including liver injury, cardiovascular events, and hormonal imbalances" [9].

Clinical Bottom Line

YK-11 has no completed human pharmacokinetic study, no Phase I safety trial, and no efficacy data beyond a single 2011 cell-line experiment. The case literature documents hepatotoxicity at typical self-administered doses. Legal status under FDA and WADA regulations creates real professional and health consequences for users. Patients at HealthRX who present with interest in YK-11 are counseled to quantify their actual goals, measure baseline testosterone and metabolic panels, and select from the evidence-supported options listed above.

Any patient presenting with prior SARM use should have a baseline liver function panel (ALT, AST, ALP, total bilirubin), complete blood count with hematocrit, lipid panel, and morning total testosterone drawn before any new intervention is considered.